{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:10:35Z","timestamp":1762866635436,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1053\/j.ajkd.2015.03.004","type":"journal-article","created":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T12:36:52Z","timestamp":1432125412000},"page":"811-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Acute Response to Tolvaptan in ADPKD: A Window to Predict Long-term Efficacy?"],"prefix":"10.1053","volume":"65","author":[{"given":"Bharathi","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene B.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2015.03.004_bib1","first-page":"1","article-title":"Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families","volume":"328","author":"Dalgaard","year":"1957","journal-title":"Acta Med Scand Suppl"},{"issue":"10","key":"10.1053\/j.ajkd.2015.03.004_bib2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"issue":"39","key":"10.1053\/j.ajkd.2015.03.004_bib3","doi-asserted-by":"crossref","first-page":"40419","DOI":"10.1074\/jbc.M405079200","article-title":"Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J\u00a0Biol Chem"},{"issue":"25","key":"10.1053\/j.ajkd.2015.03.004_bib4","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2015.03.004_bib5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","article-title":"Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function","volume":"65","author":"Boertien","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2015.03.004_bib6","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease","volume":"84","author":"Boertien","year":"2013","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2015.03.004_bib7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.bbadis.2011.06.012","article-title":"Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD)","volume":"1812","author":"Norman","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1053\/j.ajkd.2015.03.004_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2015.03.004_bib9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.V76842","article-title":"Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action","volume":"7","author":"Bouby","year":"1996","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4, pt 2","key":"10.1053\/j.ajkd.2015.03.004_bib10","first-page":"F973","article-title":"Effect of water intake on the progression of chronic renal failure in the 5\/6 nephrectomized rat","volume":"258","author":"Bouby","year":"1990","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1053\/j.ajkd.2015.03.004_bib11","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/ki.1996.232","article-title":"Direct and indirect cost of urea excretion","volume":"49","author":"Bankir","year":"1996","journal-title":"Kidney Int"},{"issue":"24","key":"10.1053\/j.ajkd.2015.03.004_bib12","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2015.03.004_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615005260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615005260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:30:49Z","timestamp":1759458649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638615005260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0272638615005260"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.03.004","relation":{},"ISSN":["0272-6386"],"issn-type":[{"type":"print","value":"0272-6386"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Response to Tolvaptan in ADPKD: A Window to Predict Long-term Efficacy?","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.11.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}